返回ChemicalBook首页>CAS数据库列表>107534-93-0

107534-93-0

中文名称 安五脂素
英文名称 Anwuligan
CAS 107534-93-0
分子式 C20H24O4
分子量 328.4
MOL 文件 107534-93-0.mol
更新日期 2024/05/13 10:59:07
107534-93-0 结构式 107534-93-0 结构式

基本信息

中文别名
安五脂素
安五酯素
安五脂素对照品
安五脂素标准品
安五脂素, >98%
安五脂素 (安五酯素)
安五脂素, 来源于五味子
ANWULIGAN 安五酯素
英文别名
Calophyn
Anwuligan
Macelignan
ANWULIGNAN
(+)-Anwulignan
Macelignan, >98%
Anwuligan(Macelignan)
Macelignan >=98% (HPLC)
Anwuligan, 98%, from Schisandra chinensis
4-(2S,3R)-4-(1,3-benzodioxol-5-yl-2-3-dimetybty]-2_methoxyphenol
所属类别
生物化工:提取物

物理化学性质

外观性状白色结晶粉末,可溶于甲醇、乙醇、DMSO等有机溶剂,来源于五味子Schisandra chinensis 的根或皮。
熔点70-71℃
沸点467.0±40.0 °C(Predicted)
密度1.159
闪点236℃
储存条件-20°C储存
溶解度DMSO : ≥ 30 mg/mL (91.35 mM)
酸度系数(pKa)10.19±0.20(Predicted)
形态粉末
颜色白色
LogP5.220 (est)

应用领域

用途1
用于含量测定/鉴定/药理实验等
药理药效:抗肿瘤、凝血
用途2
安五脂素有抗肿瘤、凝血的作用。

安全数据

海关编码29329990

常见问题列表

生物活性
Macelignan ((+)-Anwulignan; Anwuligan) 是一种从肉豆蔻中分离得到的生物活性木脂素 (lignan)。Macelignan 具有多种药理活性,包括抗炎、抗癌、抗糖尿病和神经保护活性。
靶点

COX-2

体外研究

Macelignan (1-50 μM; 72 hours) does not reduce cell viability alone, however, UVB treatment, even at the lowest dose of 30 mJ/cm 2 , reduces HaCaT cell viability in a dose-dependent mannner,it reduces approximately 80% of control values at 100 μM in hacat cells.Macelignan (0.1-1 μM; 24 hours) decreases COX-2 expression in a concentration-dependent manner,and at the highest concentration of macelignan (1 μM) , COX-2 expression is inhibited by almost 50% in hacat cells.

Cell Viability Assay

Cell Line: Hacat cells
Concentration: 1 μM; 2.5 μM; 5 μM; 10 μM; 15 μM; 50 μM
Incubation Time: 72 hours
Result: Induced cell death by UVB irradiation at 30 mJ/cm 2 from 10 μM.

Western Blot Analysis

Cell Line: Hacat cells
Concentration: 0.1 μM; 0.5 μM;1 μM
Incubation Time: 24 hours
Result: Reduced UVB-induced COX-2 expression in cells.
体内研究

Macelignan (oral administration; 15 mg/kg; every day for three weeks) exhibits in vivo anti-diabetic effects. The baseline (day 0) fasting blood glucose levels does not differ between groups; at the end of the experiment, the values of the Macelignan-treated group are significantly lower compared to the diabetic control group in C57BL/KsJ- db/db mice.

Animal Model: Male C57BL/KsJ- db/db mice
Dosage: 15 mg/kg
Administration: Oral administration; 15 mg/kg; every day for three weeks
Result: Significantly reduced the blood glucose levels in mice.
"107534-93-0" 相关产品信息
66056-22-2 66280-25-9 60546-10-3 1234186-01-6 82425-45-4 83864-69-1 73036-31-4 130783-32-3 82508-31-4 81-14-1 487-41-2 61281-38-7 31008-19-2